Objective: The assessment of disease activity in Takayasu arteritis (TA) is difficult in clinical situations because clinical symptoms and laboratory parameters do not always reflect the actual inflammation of the arterial wall. We undertook this study to comprehensively investigate the role of 18F‐fluorodeoxyglucose–positron emission tomography (FDG‐PET) in the assessment of disease activity in patients with TA.Methods: We performed a retrospective chart review of 53 FDG‐PET scans in 38 patients with TA. We measured 18F‐fluorodeoxyglucose (18F‐FDG) accumulation in the vascular wall of the large vessel using semiquantitative (visual grade) and quantitative (standard uptake value intensity) analyses. Clinical disease activity was evaluated based on the National Institutes of Health criteria for active TA, and erythrocyte sedimentation rates (ESRs) and C‐reactive protein (CRP) levels were measured.Results: At baseline, active vascular 18F‐FDG uptake (visual grade ≥2) was observed in 18 of 24 patients with active disease and in 5 of 14 patients with inactive disease. There was a significant association between clinical disease activity and disease activity judged by FDG‐PET (P = 0.008). Visual grade, standard uptake value intensity, and the number of vascular lesions with active 18F‐FDG uptake were significantly higher in patients with active disease and correlated well with the ESR and CRP levels. In 15 followup FDG‐PET scans, the changes in visual grade, areas of active vascular 18F‐FDG uptake, and standard uptake value intensity reflected changes in clinical disease activity.Conclusion: 18F‐FDG uptake was associated with clinical disease activity and markers of inflammation, and FDG‐PET reflected changes in clinical disease activity in patients with TA. FDG‐PET may be a useful tool for aiding in the assessment of disease activity in patients with TA.
The aim of this study was to investigate the prevalence and associated factors of glucocorticoid-induced diabetes mellitus (GDM) in patients with systemic lupus erythematosus (SLE) receiving high-dose glucocorticoid therapy. Patients with SLE who had received high-dose glucocorticoid therapy (prednisolone ≥1 mg/kg/day) at Yonsei University Medical Center, Seoul, Korea, were recruited between January 1999 and June 2009. In total 127 patients with SLE were evaluated. Sixteen (12.6%) of them developed GDM after high-dose glucocorticoid therapy (95% confidence interval, 6.8–18.4%). Univariate analysis showed that old age, family history of diabetes mellitus (DM), hypertension, higher body mass index, higher mean dose of prednisolone before high-dose glucocorticoid therapy, and concurrent use of mycophenolate mofetil (MMF) were factors that would increase the likelihood of GDM. Multivariate analysis determined that age, family history of DM, mean dose of prednisolone before high-dose glucocorticoid therapy and concurrent use of MMF were independent associated factors for GDM. In summary, GDM was developed among 12.6% of patients with SLE after high-dose glucocorticoid therapy. Old age, family history of DM, higher mean dose of prednisolone before high-dose glucocorticoid therapy and concurrent use of MMF were determined to be factors responsible for increasing the risk of developing GDM.